FDA To Update Quality Metrics Guidance
Executive Summary
It's the only addition to the agency's 2016 agenda.
You may also be interested in...
Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?
Brand and generic industries are on opposite sides of spectrum on most issues; there is mutual opposition, however, to the use of a meaningless four-letter suffix in the proper name of a product.
Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?
Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.
Biosimilar Labeling: FDA Says Leave Comparability Data Out
Data developed to show no clinically meaningful differences with the reference product could confuse prescribers, agency says in new draft guidance.